Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy  

作　　者：Lisa B E Shields Michael W Daniels Nataliya Mar Arash Rezazadeh Kalebasty 

机构地区：[1]Norton Neuroscience Institute,Norton Healthcare,Louisville,KY 40202,United States [2]Department of Bioinformatics and Biostatistics,University of Louisville,Louisville,KY 40292,United States [3]Division of Hematology/Oncology,Department of Medicine,UCI Medical Center,Orange,CA 92868,United States

出　　处：《World Journal of Clinical Oncology》2021年第3期183-194,共12页世界临床肿瘤学杂志（英文版）

摘　　要：BACKGROUND Testicular germ cell tumor(TGCT)is the most curable solid tumor and most common cancer among men 18-39 years.While cisplatin-based chemotherapy has significantly lengthened the survival of patients with TGCT,it is associated with a high rate of thromboembolic events(TEE).AIM To summarize our single-center experience highlighting patients who were diagnosed with TGCT and received platinum-based chemotherapy,with special attention to those patients who suffered a TEE.METHODS A retrospective analysis of the medical records and imaging studies of 68 consecutive individuals who were diagnosed with TGCT and received platinumbased chemotherapy at our Institution in a metropolitan community between January 1,2014 and December 31,2019.RESULTS A total of 19(28%)patients experienced a TEE following orchiectomy which occurred during chemotherapy in 13(68%)of these patients.Patients with a higher pathologic stage(stage III)were significantly(P=0.023)more likely to experience a TEE compared to patients who had a lower stage.Additionally,patients who were treated with 3 cycles of bleomycine,etoposide,and cisplatin and 1 cycle of etoposide and cisplatin or 4 cycles of etoposide and cisplatin were significantly 5(P=0.02)times more likely to experience a TEE compared to patients who were treated with only 3 cycles of bleomycine,etoposide,and cisplatin.CONCLUSION Due to numerous factors that predispose to a TEE such as large retroperitoneal disease,higher clinical stage,greater number of chemotherapy cycle,central venous catheter,cigarette smoking,and possible cannabis use,high-risk ambulatory patients with TGCT treated with cisplatin-based chemotherapy may benefit from prophylactic anticoagulation.Randomized studies to evaluate the safety and efficacy of prophylactic anticoagulants are warranted in this young patient population generally devoid of medical co-morbidities.

关 键 词：ONCOLOGY Testicular cancer THROMBOEMBOLIC CISPLATIN Pulmonary embolism THROMBOPROPHYLAXIS 

分 类 号：R737.21[医药卫生—肿瘤]